BCAB Earnings & Financial Statements
BioAtla, Inc.
$1.30
+$0.02(+1.56%)
32
Overall
40
Value
27
Tech
31
Quality
Market Cap
$2.13M
Volume
3.91K
52W Range
$1.07 - $71.50
Target Price
$10.00
BCAB earnings and financial statements: BioAtla, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
BCAB Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | - | $11.00M | - | - | $300.0K |
| Operating income | -$59.30M | -$73.94M | -$129.69M | -$108.14M | -$96.44M |
| EBITDA | -$59.23M | -$68.85M | -$122.24M | -$106.94M | -$94.07M |
| Net income | -$59.61M | -$69.78M | -$123.46M | -$106.48M | -$95.40M |
| EPS (diluted) | $-1.01 | $-72.00 | $-129.00 | $-137.00 | $-138.00 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $13.83M | $52.42M | $119.66M | $225.74M | $254.42M |
| Total liabilities | $50.02M | $38.16M | $48.99M | $45.40M | $43.60M |
| Shareholders’ equity | -$36.19M | $14.27M | $70.67M | $180.34M | $210.82M |
| Cash and equivalents | $7.12M | $49.05M | $111.47M | $215.51M | $244.98M |
| Long-term debt | $4.77M | - | $836.0K | $2.46M | $3.98M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$48.20M | -$71.94M | -$104.02M | -$90.42M | -$62.21M |
| Capital expenditure | - | - | -$98.0K | -$268.0K | -$924.0K |
| Free cash flow | -$48.20M | -$71.94M | -$104.11M | -$90.69M | -$63.14M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | BCAB | $1.30 | +1.6% | 3.91K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |